21,270 Shares in Bruker Corporation $BRKR Bought by SummitTX Capital L.P.

SummitTX Capital L.P. acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,270 shares of the medical research company’s stock, valued at approximately $768,000.

Other institutional investors also recently bought and sold shares of the company. Orbis Allan Gray Ltd purchased a new stake in shares of Bruker in the second quarter valued at about $192,735,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Bruker by 2,963.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock worth $111,488,000 after buying an additional 2,289,269 shares during the last quarter. AQR Capital Management LLC increased its position in Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the period. Franklin Resources Inc. increased its position in Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after acquiring an additional 1,756,460 shares during the period. Finally, Millennium Management LLC raised its stake in Bruker by 222.6% during the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after acquiring an additional 1,269,316 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BRKR shares. Guggenheim increased their price objective on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Stifel Nicolaus set a $45.00 target price on Bruker in a report on Friday, May 8th. UBS Group set a $60.00 price target on Bruker in a research note on Wednesday, June 24th. JPMorgan Chase & Co. increased their price target on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Finally, Citigroup lifted their price objective on shares of Bruker from $44.00 to $60.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $56.79.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $64.34 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The company has a market cap of $9.79 billion, a P/E ratio of -268.08, a PEG ratio of 1.98 and a beta of 1.29. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.54. The company has a 50-day moving average price of $57.81 and a 200 day moving average price of $46.54.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. The company had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts predict that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were paid a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s payout ratio is -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.